Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Drug Metabolism & Disposition
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Drug Metabolism & Disposition

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit dmd on Facebook
  • Follow dmd on Twitter
  • Follow ASPET on LinkedIn
Research ArticleArticle

VALPROYL-DEPHOSPHOCoA: A NOVEL METABOLITE OF VALPROATE FORMED IN VITRO IN RAT LIVER MITOCHONDRIA

Margarida F. B. Silva, Lodewijk IJlst, Paul Allers, Cornelis Jakobs, Marinus Duran, Isabel Tavares de Almeida and Ronald J. A. Wanders
Drug Metabolism and Disposition November 2004, 32 (11) 1304-1310; DOI: https://doi.org/10.1124/dmd.32.11.1304
Margarida F. B. Silva
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lodewijk IJlst
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul Allers
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Cornelis Jakobs
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marinus Duran
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Isabel Tavares de Almeida
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ronald J. A. Wanders
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The mitochondrial metabolism of valproic acid (VPA) was investigated in vitro to elucidate its β-oxidation pathway since the characterization of VPA intermediates in the acyl-CoA thioester form, and not just in their free acid form, has not been fully achieved. Intact rat liver mitochondria were incubated with [4,5-3H2]VPA and [2-3H]VPA. The respective intermediates, valproyl-CoA, Δ2(E)-valproyl-CoA, 3-hydroxyvalproyl-CoA, and 3-oxovalproyl-CoA were analyzed by reverse phase high performance liquid chromatography (HPLC) with radioisotope and UV detection. An unknown metabolite, originating from both labeled substrates, was detected. It was identified as valproyl-dephosphoCoA (valproyl-dephCoA) by fast atom bombardment mass spectrometry (FAB-MS) analysis of the corresponding HPLC peak fraction. The FAB-MS spectrum of the authentic chemically synthesized valproyl-dephCoA proved to be consistent with that of the unknown compound. Valproyl-dephCoA is produced from valproyl-CoA in mitochondria, probably via a phosphatase-catalyzed reaction. This conversion was shown to be more dependent on the energy state involving [AXP] ([AXP] = [ATP] + [ADP] + [AMP]) and [phosphate] concentrations rather than the strict mitochondrial [ATP]/[ADP] ratio. The results indicate that higher concentrations of AXP and phosphate inhibit the dephosphorylation of valproyl-CoA. A complete understanding of the toxic significance of valproyl-dephCoA formation in vivo as a potential inhibitor of fatty acid β-oxidation is important to clarify the pathogenesis of VPA-associated hepatotoxicity.

Footnotes

  • This work was financially supported by “Fundação para a Ciência e a Tecnologia” (Lisboa, Portugal) (POCTI/FCB/48800/2002 with partial funding of Fundo Europeu de Desenvolvimento Regional).

  • ABBREVIATIONS: VPA, 2-n-propylpentanoic acid or valproic acid; Δ2(E)-VPA, 2-n-propyl-trans 2-pentenoic acid; CoA, coenzyme A; dephCoA, dephosphocoenzyme A; Pi, orthophosphate; AMP, adenosine-5′-monophosphate; ADP, adenosine-5′-diphosphate; ATP, adenosine-5′-triphosphate; ATP-γ-S, adenosine-5′-O-(3-thiotriphosphate); AXP, total adenine nucleotides (AMP + ADP + ATP); MOPS, 3-[N-morpholino]propane-sulfonic acid; EGTA, ethylene glycol-bis(β-aminoethyl ether)-N,N,N′,N′-tetraacetic acid; SEM buffer, sucrose/EGTA/MOPS buffer; KPi buffer, potassium dihydrogen phosphate buffer; FAB-MS, fast atom bombardment mass spectrometry; HPLC, high performance liquid chromatography; radio-HPLC, high performance liquid chromatography with radiochemical detection; RLM, rat liver mitochondria.

    • Received October 10, 2003.
    • Accepted July 22, 2004.
  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

 

DMD articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Drug Metabolism and Disposition: 32 (11)
Drug Metabolism and Disposition
Vol. 32, Issue 11
1 Nov 2004
  • Table of Contents
  • About the Cover
  • Index by author
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Drug Metabolism & Disposition article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
VALPROYL-DEPHOSPHOCoA: A NOVEL METABOLITE OF VALPROATE FORMED IN VITRO IN RAT LIVER MITOCHONDRIA
(Your Name) has forwarded a page to you from Drug Metabolism & Disposition
(Your Name) thought you would be interested in this article in Drug Metabolism & Disposition.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

VALPROYL-DEPHOSPHOCoA: A NOVEL METABOLITE OF VALPROATE FORMED IN VITRO IN RAT LIVER MITOCHONDRIA

Margarida F. B. Silva, Lodewijk IJlst, Paul Allers, Cornelis Jakobs, Marinus Duran, Isabel Tavares de Almeida and Ronald J. A. Wanders
Drug Metabolism and Disposition November 1, 2004, 32 (11) 1304-1310; DOI: https://doi.org/10.1124/dmd.32.11.1304

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleArticle

VALPROYL-DEPHOSPHOCoA: A NOVEL METABOLITE OF VALPROATE FORMED IN VITRO IN RAT LIVER MITOCHONDRIA

Margarida F. B. Silva, Lodewijk IJlst, Paul Allers, Cornelis Jakobs, Marinus Duran, Isabel Tavares de Almeida and Ronald J. A. Wanders
Drug Metabolism and Disposition November 1, 2004, 32 (11) 1304-1310; DOI: https://doi.org/10.1124/dmd.32.11.1304
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Role of Human MSRA on Sulindac Activation
  • Determination of Acyl-, O-, and N-Glucuronide
  • Uptake as the RDS in Pevonedistat Hepatic Clearance
Show more Articles

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About DMD
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Journal of Pharmacology and Experimental Therapeutics
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-009X (Online)

Copyright © 2022 by the American Society for Pharmacology and Experimental Therapeutics